Ewing Sarcoma Clinical Trials in Boston, Massachusetts

4 studies are recruiting for ewing sarcoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

    Stage
    Phase 1
    Ages
    0 to 25
    Site
    Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts
    Locations
    71 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06395103 on ClinicalTrials.gov

  2. Lurbinectedin in FET-Fused Tumors

    The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

    Stage
    Phase 1
    Ages
    10 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Locations
    6 in total
    Run by
    Children's Hospital of Philadelphia

    See if you can join NCT05918640 on ClinicalTrials.gov

  3. Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

    The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

    Stage
    Phase 1
    Ages
    2 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    9 in total
    Run by
    Amgen

    See if you can join NCT07297979 on ClinicalTrials.gov

  4. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

    A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

    Stage
    Phase 1
    Ages
    16 and older
    Site
    Mass General Brigham Cancer Institute, Boston, Massachusetts
    Locations
    6 in total
    Run by
    SEED Therapeutics, Inc.

    See if you can join NCT07197554 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.